{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:40:13Z","timestamp":1781876413980,"version":"3.54.5"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["CVU 737080"],"award-info":[{"award-number":["CVU 737080"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.vaccine.2020.11.073","type":"journal-article","created":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T01:36:04Z","timestamp":1607996164000},"page":"173-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Preclinical evaluation of tuberculosis vaccine candidates: Is it time to harmonize study design and readouts for prioritizing their development?"],"prefix":"10.1016","volume":"39","author":[{"given":"Mario Alberto","family":"Flores-Valdez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian Alfredo","family":"Segura-Cerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.11.073_b0005","unstructured":"WHO WHO. Global tuberculosis report. In: ONU, editor; 2020."},{"key":"10.1016\/j.vaccine.2020.11.073_b0010","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/resp.13245","article-title":"Tuberculosis vaccines: Opportunities and challenges","volume":"23","author":"Zhu","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.vaccine.2020.11.073_b0015","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/infdis\/jiw228","article-title":"Vaccination against tuberculosis with whole-cell mycobacterial vaccines","volume":"214","author":"Scriba","year":"2016","journal-title":"J Infect Dis."},{"key":"10.1016\/j.vaccine.2020.11.073_b0020","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00103-019-03065-y","article-title":"New vaccines against tuberculosis","volume":"63","author":"Kaufmann","year":"2020","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz."},{"key":"10.1016\/j.vaccine.2020.11.073_b0025","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/j.vaccine.2009.12.083","article-title":"The second Geneva Consensus: Recommendations for novel live TB vaccines","volume":"28","author":"Walker","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.11.073_b0030","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TBTB2-0029-2016","article-title":"Pathology of tuberculosis: how the pathology of human tuberculosis informs and directs animal models","volume":"5","author":"Basaraba","year":"2017","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.vaccine.2020.11.073_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102761","article-title":"Live attenuated TB vaccines representing the three modern Mycobacterium tuberculosis lineages reveal that the Euro-American genetic background confers optimal vaccine potential","volume":"55","author":"Perez","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2020.11.073_b0040","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.1016\/j.vaccine.2016.08.035","article-title":"The BCGDeltaBCG1419c strain, which produces more pellicle in vitro, improves control of chronic tuberculosis in vivo","volume":"34","author":"Pedroza-Roldan","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.11.073_b0045","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00097-20","article-title":"The diversity outbred mouse population is an improved animal model of vaccination against tuberculosis that reflects heterogeneity of protection","volume":"5","author":"Kurtz","year":"2020","journal-title":"mSphere"},{"key":"10.1016\/j.vaccine.2020.11.073_b0050","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijid.2017.01.030","article-title":"Experimental animal modelling for TB vaccine development","volume":"56","author":"Cardona","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.11.073_b0055","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1574-6976.2008.00118.x","article-title":"Influence of BCG vaccine strain on the immune response and protection against tuberculosis","volume":"32","author":"Ritz","year":"2008","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.vaccine.2020.11.073_b0060","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1172\/JCI24617","article-title":"Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin","volume":"115","author":"Grode","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2020.11.073_b0065","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/infdis\/jir592","article-title":"Recombinant BCG DeltaureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses","volume":"204","author":"Desel","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.11.073_b0070","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/infdis\/jiu347","article-title":"Central memory CD4+ T cells are responsible for the recombinant Bacillus Calmette-Guerin DeltaureC::hly vaccine's superior protection against tuberculosis","volume":"210","author":"Vogelzang","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.11.073_b0075","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.micinf.2016.03.005","article-title":"Post-exposure vaccination with the vaccine candidate Bacillus Calmette-Guerin DeltaureC::hly induces superior protection in a mouse model of subclinical tuberculosis","volume":"18","author":"Gengenbacher","year":"2016","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2020.11.073_b0080","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/vaccines1020120","article-title":"Nonclinical development of BCG replacement vaccine candidates","volume":"1","author":"Velmurugan","year":"2013","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2020.11.073_b0085","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1128\/CVI.00435-13","volume":"20","author":"Buddle","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2020.11.073_b0090","doi-asserted-by":"crossref","DOI":"10.3791\/54440","article-title":"Protective efficacy and pulmonary immune response following subcutaneous and intranasal BCG administration in mice","author":"Uranga","year":"2016","journal-title":"J Vis Exp"},{"key":"10.1016\/j.vaccine.2020.11.073_b0095","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1128\/CVI.00700-13","article-title":"Pulmonary Mycobacterium bovis BCG vaccination confers dose-dependent superior protection compared to that of subcutaneous vaccination","volume":"21","author":"Aguilo","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2020.11.073_b0100","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-genet-022820-085940","article-title":"Genetic diversity in mycobacterium tuberculosis clinical isolates and resulting outcomes of tuberculosis infection and disease","author":"Peters","year":"2020","journal-title":"Annu Rev Genet"},{"key":"10.1016\/j.vaccine.2020.11.073_b0105","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz1767","article-title":"A systematic approach to simultaneously evaluate safety, immunogenicity, and efficacy of novel tuberculosis vaccination strategies","volume":"6","author":"Muruganandah","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2020.11.073_b0110","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01686-16","article-title":"Mucosal BCG vaccination induces protective lung-resident memory T cell populations against tuberculosis","volume":"7","author":"Perdomo","year":"2016","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2020.11.073_b0115","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3389\/fimmu.2019.00532","article-title":"BCG vaccination prevents reactivation of latent lymphatic murine tuberculosis independently of CD4(+) T Cells","volume":"10","author":"Sathkumara","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2020.11.073_b0120","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.tube.2016.09.004","article-title":"Alternative BCG delivery strategies improve protection against Mycobacterium tuberculosis in non-human primates: Protection associated with mycobacterial antigen-specific CD4 effector memory T-cell populations","volume":"101","author":"Sharpe","year":"2016","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.vaccine.2020.11.073_b0125","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41586-019-1817-8","article-title":"Prevention of tuberculosis in macaques after intravenous BCG immunization","volume":"577","author":"Darrah","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2020.11.073_b0130","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3389\/fimmu.2017.01203","article-title":"TBVAC2020: advancing tuberculosis vaccines from discovery to clinical development","volume":"8","author":"Kaufmann","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2020.11.073_b0135","doi-asserted-by":"crossref","DOI":"10.1093\/femspd\/ftx079","article-title":"Recent mouse models and vaccine candidates for preventing chronic\/latent tuberculosis infection and its reactivation","volume":"75","author":"Pedroza-Roldan","year":"2017","journal-title":"Pathog Dis"},{"key":"10.1016\/j.vaccine.2020.11.073_b0140","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/S2214-109X(18)30452-2","article-title":"Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study","volume":"7","author":"Harris","year":"2019","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2020.11.073_b0145","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3389\/fmicb.2020.01339","article-title":"Respiratory immunization with a whole cell inactivated vaccine induces functional mucosal immunoglobulins against tuberculosis in mice and non-human primates","volume":"11","author":"Aguilo","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2020.11.073_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007643","article-title":"A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates","volume":"15","author":"Rodo","year":"2019","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2020.11.073_b0155","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00776-17","article-title":"Toward tuberculosis vaccine development: recommendations for nonhuman primate study design","volume":"86","author":"Laddy","year":"2018","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.11.073_b0160","doi-asserted-by":"crossref","unstructured":"Sathkumara HD, Muruganandah V, Cooper MM, Field MA, Alim MA, Brosch R, et al. Mucosal delivery of ESX-1\u2013expressing BCG strains provides superior immunity against tuberculosis in murine type 2 diabetes. Proc Natl Acad Sci 2020.","DOI":"10.1073\/pnas.2003235117"},{"key":"10.1016\/j.vaccine.2020.11.073_b0165","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133788","article-title":"BCG vaccination reduces the mortality of Mycobacterium tuberculosis-infected type 2 diabetes mellitus mice","volume":"5","author":"Radhakrishnan","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.vaccine.2020.11.073_b0170","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41541-020-0169-6","article-title":"BCG and BCGDeltaBCG1419c protect type 2 diabetic mice against tuberculosis via different participation of T and B lymphocytes, dendritic cells and pro-inflammatory cytokines","volume":"5","author":"Segura-Cerda","year":"2020","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2020.11.073_b0175","doi-asserted-by":"crossref","first-page":"20848","DOI":"10.1073\/pnas.2003235117","article-title":"Mucosal delivery of ESX-1-expressing BCG strains provides superior immunity against tuberculosis in murine type 2 diabetes","volume":"117","author":"Sathkumara","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.11.073_b0180","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1128\/IAI.74.3.1718-1724.2006","article-title":"Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB\/c model of progressive pulmonary tuberculosis","volume":"74","author":"Castillo-Rodal","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.11.073_b0185","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/mt.2015.216","article-title":"Variable virulence and efficacy of BCG vaccine strains in mice and correlation with genome polymorphisms","volume":"24","author":"Zhang","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2020.11.073_b0190","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2003235117","article-title":"Mucosal delivery of ESX-1-expressing BCG strains provides superior immunity against tuberculosis in murine type 2 diabetes","author":"Sathkumara","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2020.11.073_b0195","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/cid\/civ454","article-title":"Editorial commentary: different strains of bacillus calmette-guerin vaccine have very different effects on tuberculosis and on unrelated infections","volume":"61","author":"Shann","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.11.073_bib196","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101431","article-title":"Key recent advances in TB vaccine development and understanding of protective immune responses against Mycobacterium tuberculosis","author":"Scriba","year":"2020","journal-title":"Semin Immunol"},{"key":"10.1016\/j.vaccine.2020.11.073_bib197","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01203","article-title":"TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development","volume":"8","author":"Kaufmann","year":"2017","journal-title":"Front. Immunol."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20315565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20315565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:52:35Z","timestamp":1759402355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20315565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0264410X20315565"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.073","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluation of tuberculosis vaccine candidates: Is it time to harmonize study design and readouts for prioritizing their development?","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}